Shensong Yangxin Capsule
Shop NowOverview
What is Shensong Yangxin Capsule?
Shensong Yangxin Capsule is a 12-ingredient proprietary Traditional Chinese Medicine (TCM) formula primarily used to manage premature ventricular contractions (PVCs) associated with coronary heart disease and related palpitations.
Recommended Use
Official product information describes use for coronary heart disease with ventricular premature beats and associated symptoms in the labeled traditional context.
Product Information
| Chinese name | 参松养心胶囊 |
|---|---|
| Alternative Name | Shensong Yangxin Jiaonang |
| Brand | Yiling |
| Manufacturer | Shijiazhuang Yiling Pharmaceutical Co., Ltd. |
| China Drug Approval No. | Z20103032 |
| Drug Standard | Chinese Pharmacopoeia 2020, Volume I |
| Dosage form | capsule |
| Strength | 0.4 g per capsule |
| Individual package | 0.4 g × 36 capsules |
| GTIN | 6952378200039 |
| Prescription Status in China | Prescription medicine. |
Ingredients
Shensong Yangxin Capsule is made from 12 herbs: Ginseng root (Ren Shen), Ophiopogon root (Mai Dong), Cornus fruit (Shan Zhu Yu), Danshen root (Dan Shen), Sour jujube seed (Suan Zao Ren), Chinese Taxillus twig (Sang Ji Sheng), Red peony root (Chi Shao), Eupolyphaga (Tu Bie Chong), Nardostachys root (Gan Song), Coptis rhizome (Huang Lian), Schisandra sphenanthera fruit (Nan Wu Wei Zi), and Dragon bone (Long Gu).
Benefits & Uses
Benefits & Common Uses
Shensong Yangxin Capsule is commonly used in China for selected heart-rhythm concerns, including:
- Premature ventricular contractions (PVCs)
- Palpitations
- Shortness of breath
- Fatigue
- Chest discomfort
- Sleep disturbance associated with the indicated TCM pattern
How It Works
Modern research has investigated bioactive constituents in several ingredients in the Shensong Yangxin Capsule formula, providing insight into biological activities that may help explain aspects of its traditional use.
-
Ginseng root (Ren Shen)
Key bioactive constituents of Ginseng root (Ren Shen), including ginsenoside Rb1, ginsenoside Rg1, and Panax ginseng polysaccharides, have been investigated for immune-modulating, metabolic, and vascular-related biological activities.
-
Ophiopogon root (Mai Dong)
Key bioactive constituents of Ophiopogon root (Mai Dong), including ophiopogonin D, methylophiopogonanone A, and MDG-1, have been investigated for anti-inflammatory, antioxidant, and cardiovascular biological activities.
-
Cornus fruit (Shan Zhu Yu)
Cornus officinalis fruit (Shan Zhu Yu) and isolated iridoids such as morroniside have been examined in cell and animal models, especially for renal and metabolic effects; human efficacy of the medicinal fruit remains unestablished.
-
Danshen root (Dan Shen)
Key bioactive constituents of Danshen root (Dan Shen), including tanshinone IIA, cryptotanshinone, salvianolic acid B, and danshensu, have been investigated for vascular-related, anti-inflammatory, antioxidant, and immune-modulating biological activities.
-
Sour jujube seed (Suan Zao Ren)
Key bioactive constituents of Stir-fried sour jujube seed (Chao Suan Zao Ren), including jujuboside A, spinosin, and 6-feruloylspinosin, have been investigated for sleep-related, GABA-receptor-interacting, and anxiolytic biological activities.
Traditional Functions & Uses
益气养阴，活血通络，清心安神
Tonifies qi and nourishes yin, promotes blood circulation through the meridians, clears the heart, and calms the mind.
- Coronary heart disease with ventricular premature beats in the labeled traditional context.
Traditional pattern terminology is not a biomedical diagnosis.
Shensong Yangxin Capsule is classified as a prescription medicine in China. This Learn information is for educational purposes only. Always consult a healthcare provider before starting TCM treatments.
Safety
Adverse Reactions
- Gastrointestinal symptoms, rash, itching, or dizziness have been reported in the reviewed product information.
Contraindications
- Do not use if allergic to this product or any of its ingredients.
Precautions
Consult a physician or pharmacist before use during pregnancy or breastfeeding.
Use in children only under professional guidance.
Ask a clinician or pharmacist to review all medicines and supplements before use.
Evidence
Evidence at a Glance
Randomized trials have evaluated selected ventricular-premature-beat and post-ablation rhythm populations, but population, background care, and evidence limits restrict individual conclusions.
Evaluation of the traditional Chinese Medicine Shensongyangxin capsule on treating premature ventricular contractions: a randomized, double-blind, controlled multicenter trial
8 weeks
View More
Population: 759 people in two selected PVC populations
Indication: Frequent premature ventricular contractions
Intervention: Shensong Yangxin Capsule
Comparison: Placebo or mexiletine
Sample size: 759
Duration: 8 weeks
Reported findings
8 weeks
Interpretation
Evidence is specific to the studied population and regimen.
Limitations
Selected population and duration; does not establish individual suitability.
Evaluation of the traditional Chinese Medicine Shensongyangxin capsule on treating premature ventricular contractions: a randomized, double-blind, controlled multicenter trial
Year: 2011
Study type: Randomized Double-blind Multicenter Trial
Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes
12 weeks
View More
Population: 465 patients with congestive heart failure and frequent ventricular premature complexes
Indication: Frequent PVCs in congestive heart failure
Intervention: Shensong Yangxin Capsule
Comparison: Placebo
Sample size: 465
Duration: 12 weeks
Reported findings
12 weeks
Interpretation
Evidence is specific to the studied population and regimen.
Limitations
Selected population and duration; does not establish individual suitability.
Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes
Year: 2017
Study type: Randomized Double-blind Multicenter Trial
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial
12 months
View More
Population: 920 patients with persistent atrial fibrillation undergoing first catheter ablation at 66 centers in China
Indication: Persistent atrial fibrillation after catheter ablation
Intervention: Shensong Yangxin Capsule plus background care
Comparison: Placebo plus background care
Sample size: 920
Duration: 12 months
Reported findings
12 months
Interpretation
Evidence is specific to the studied population and regimen.
Limitations
Selected population and duration; does not establish individual suitability.
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial
Year: 2024
Study type: Multicenter Randomized Double-blind Placebo-controlled Trial
Verification
- Brand relationship confirmed
- Manufacturer legal name confirmed
- Approval number confirmed
- Current packaging matched
- Registration holder / manufacturer checked
- Authenticity method checked
- Label/source evidence recorded
Official Label Dosage
Take 2–4 capsules orally three times daily
A purchase option’s quantity does not define how long you should take the medicine.